Clinical Trials Logo
  1. Home
  2. Hypercholesterolemia, Familial
  3. NCT01375751

Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study — RUTHERFORD  

Hypercholesterolemia, Familial Clinical Trial

Official title:
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Subject With Heterozygous Familial Hypercholesterolemia

Clinical Trial Summary

The primary objective of this study was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145), compared with placebo, on percent change from baseline in LDL-C in adults with heterozygous familial hypercholesterolemia (HeFH).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01375751
Study type Interventional
Source Amgen
Contact
Status Completed
Phase Phase 2
Start date August 2, 2011
Completion date May 16, 2012
View Details
See also
  Status Clinical Trial Phase
Terminated NCT00384293 - Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED) Phase 3
Completed NCT04722068 - Regeneron 1331 Kinetics Sub-Study HoFH N/A
Completed NCT04118348 - Evaluating the Efficacy of Pediatric Lipid Screening Alerts N/A
Completed NCT00000594 - NHLBI Type II Coronary Intervention Study Phase 3
Completed NCT04526457 - Is Family Screening Improved by Genetic Testing of Familial Hypercholesterolemia N/A
Completed NCT01753232 - Safety and Efficacy of the DALI LDL-adsorber and MONET Lipoprotein Filter N/A
Completed NCT03018678 - Screening Protocol for a Gene Therapy Trial in Subjects With Homozygous Familial Hypercholesterolemia
Completed NCT00134485 - Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia Phase 3
Completed NCT00134511 - Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder Phase 3
Recruiting NCT04073797 - PET Imaging of Inflammation and Lipid Lowering Study N/A
Terminated NCT01583647 - A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158) Phase 1
Completed NCT00515307 - Bone Marrow Stem Cells as a Source of Allogenic Hepatocyte Transplantation in Homozygous Familial Hypercholesterolemia Phase 1
Recruiting NCT04656028 - Genetic Testing and Motivational Counseling for FH N/A
Terminated NCT00092833 - Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED) Phase 3
Active, not recruiting NCT04837638 - Diet Quality and Coronary Artery Calcification in Adults With Heterozygous Familial Hypercholesterolemia
Completed NCT00280995 - Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy Phase 2
Completed NCT06231459 - Expression of Pro- and Anti-inflammatory Cytokines During Anti-PCSK9 in Familial Hypercholesterolemia Phase 4
Completed NCT01524289 - Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020) Phase 3
Completed NCT00281008 - Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy Phase 2
Recruiting NCT03989167 - Clinical Decision Support for Familial Hypercholesterolemia N/A